James P Williams sold $308k of PII
SVP-CHRO at Polaris Inc.. 4,554 shares at an average of $67.53, traded Dec 5, 2025, filed Dec 8, 2025.
Score components
- +15RoleOfficer
- +14Trade size$308k at market
- 0Share of holdings soldSold 9.4% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.8%, 3m -20.0%, 6m +3.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-055883, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 5, 2025 | SOpen-market sale Common Stock | -4,554 | $67.53 | $308k | 43,878 | Dec 8, 2025 |
Related signals
Other insiders at Polaris Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 65Notable | Polaris Inc. | Benjamin D Duke President-Marine | $674k 10,090 shares | -25% | |
| 55Moderate | Polaris Inc. | Robert Paul Mack CFO, EVP - Finance + Corp Dev | $520k 7,786 shares | -9% | |
| 70Notable | Polaris Inc. | Michael T Speetzen CEO | $2.3M 35,086 shares | -20% | |
| 45Moderate | Polaris Inc. | James P Williams SVP-CHRO | $352k 5,243 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.